article thumbnail

Optum: Why payers should be watching flurry of drug development activity around eczema

FierceHealthIT

Optum: Why payers should be watching flurry of drug development activity around eczema. Mon, 05/03/2021 - 15:53.

article thumbnail

23andMe announces major Workforce Reduction amid Financial Struggles

Digital Health Global

The company’s decline Since its peak valuation of $6 billion in 2021, 23andMe’s share price has plunged by 99%. 23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. As the consumer DNA testing market has matured, growth has slowed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Anti-CRO Lindus Health Raises $55M in Series B Funding to Transform the Clinical Trial Landscape

Healthcare IT Today

The CRO industry has remained stagnant with extremely limited adoption of technology or modern approaches to streamline clinical development. From 2021 to 2022 alone, the cost of developing a single drug was estimated to have increased by almost $300M.

article thumbnail

PicnicHealth Acquires AllStripes, Fortifying its Role as the Leader in Patient-Centered Healthcare Evidence Generation

Healthcare IT Today

” The acquisition follows AllStripes’ $50 million Series B funding round in 2021 and PicnicHealth’s $60 million Series C round in 2022. . “PicnicHealth will continue both companies’ work to harness the power of patient data to support biomedical research.” Originally announced October 23rd, 2023

article thumbnail

Genialis and Debiopharm Set Up Biomarker Discovery Collaboration

Digital Health Global

Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.

article thumbnail

Accelerate Clinical Development with Patient-Centric Digital Endpoints

ActiGraph

Drug development success rates have been on the decline since 2015. Compounded by the pandemic, trial success rates fell to a 10-year low in 2021, averaging only a 5% likelihood of successful progression through all phases. 1 The machinery of clinical development urgently needs some new oil.

article thumbnail

Accelerate Clinical Development with Patient-Centric Digital Endpoints

ActiGraph

Drug development success rates have been on the decline since 2015. Compounded by the pandemic, trial success rates fell to a 10-year low in 2021, averaging only a 5% likelihood of successful progression through all phases. 1 The machinery of clinical development urgently needs some new oil.